Portland, Oregon-based Conversa Health, a virtual care and communication platform that helps health organizations stay in touch with their patients and customers, today announced that it has expanded its Series B funding round from $12 million to $20 million. The round is still co-led by Builders VC and Northwell Health’s venture arm Northwell Ventures. Additional investors include UH Ventures, the venture arm of University Hospitals and VC firms P5 Health Ventures, Epic Ventures, StartUp Health and Nassau Street Ventures, as well Genesis Merchant Capital and J-Ventures, which came in as new investors in this expanded round.
“There’s been a recognition, especially with COVID, that the need for automated and virtual — which are two big trends in healthcare — were on the horizon but now the horizon has been pulled in because of COVID and the healthcare system recognizes that that’s going to be required to be able to allow access for patients and improve both the experience for patients and providers, and get better outcomes and do it at lower cost,” Conversa CEO Murray Brozinsky told me.
Brozinsky actually believes that within the next decade, 80% of care will be done remotely. This will allow for more personalized and evidence-based care, but it will also require investments in automation.
“Conversa links providers’ EHRs and other patient data to best-of-breed interactive digital care pathways and clinical analytics engine to automate care management 24×7. This improves care plan adherence pre and post visit, reducing costs and generating better outcomes for patients,” said Builders VC partner and Conversa board member Mark Goldstein. “Conversa’s enterprise platform and library of digital pathways are used by providers to care for patients across their populations, as opposed to one-off point solutions. It fills an enormous gap in the market.”
Given the pandemic, it’s maybe no surprise that Conversa’s business also boomed. The number of customers the company its services has grown fourfold while its financial metrics are up 6x because a lot of its larger companies have expanded their use of the platform.
The team decided to expand the existing Series B round to help it capitalize on this momentum and to bring on more engineers in order to scale the platform. Brozinsky believes that the need for a platform like Conversa’s will remain after the pandemic ends. In addition, the company is also already rolling out support for vaccination programs in its service to help educate consumers but also help in monitoring efforts after people get their shots.
“Everything we’re hearing from health systems, they recognize that they need to be prepared for this to happen again, they still need to care for the core demographics that haven’t changed — this aging population — with an acute shortage of healthcare workers,” Brozinsky said. “So the need for the systems and these platforms is going to be more acute and the investment is not so much an additional cost but an enormous return.”
K Health, the virtual health care provider that uses machine learning to lower the cost of care by providing the bulk of the company’s health assessments, is launching new tools for childcare on the heels of raising cash that values the company at $1.5 billion.
The $132 million round raised in December will help the company expand and help pay for upgrades including an integration with most electronic health records — an integration that’s expected by the second quarter.
Throughout 2020 K Health has leveraged its position operating at the intersection of machine learning and consumer healthcare to raised $222 million in a single year.
This appetite from investors shows how large the opportunity is in consumer healthcare as companies look to use technology to make care more affordable.
For K Health, that means a monthly subscription to its service of $9 for unlimited access to the service and physicians on the platform, as well as a $19 per-month virtual mental health offering and a $19 fee for a one-time urgent care consultation.
To patients and investors the pitch is that the data K Health has managed to acquire through partnerships with organizations like the Israel health maintenance organization Maccabi Healthcare Services, which gave up decades of anonymized data on patients and health outcomes to train K Health’s predictive algorithm, can assess patients and aid the in diagnoses for the company’s doctors.
In theory that means the company’s service essentially acts as a virtual primary care physician, holding a wealth of patient information that, when taken together, might be able to spot underlying medical conditions faster or provide a more holistic view into patient care.
For pharmaceutical companies that could mean insights into population health that could be potentially profitable avenues for drug discovery.
In practice, patients get what they pay for.
The company’s mental health offering uses medical doctors who are not licensed psychiatrists to perform their evaluations and assessments, according to one provider on the platform, which can lead to interactions with untrained physicians that can cause more harm than good.
While company chief executive Allon Bloch is likely correct in his assessment that most services can be performed remotely (Bloch puts the figure at 90%), they should be performed remotely by professionals who have the necessary training.
There are limits to how much heavy lifting an algorithm or a generalist should do when it comes to healthcare, and it appears that K Health wants to push those limits.
“Drug referrals, acute issues, prevention issues, most of those can be done remotely,” Bloch said. “There’s an opportunity to do much better and potentially cheaper.
K Health has already seen hundreds of thousands of patients either through its urgent care offering or its subscription service and generated tens of millions in revenue in 2020, according to Bloch. He declined to disclose how many patients used the urgent care service vs. the monthly subscription offering.
Telemedicine companies, like other companies providing services remotely, have thrived during the pandemic. Teladoc and Amwell, two of the early pioneers in virtual medicine have seen their share prices soar. Companies like Hims, that provide prescriptions for elective conditions that aren’t necessarily covered by health, special purpose acquisition companies at valuations of $1.6 billion.
Backing K Health are a group of investors led by GGV Capital and Valor Equity Partners. Kaiser Permanente’s pension fund and the investment offices of the owners of 3G Capital (the Brazilian investment firm that owns Burger King and Kraft Heinz), along with 14W, Max Ventures, Pico Partners, Marcy Venture Partners, Primary Venture Partners and BoxGroup, also participated in the round.
Organizations working with the company include Maccabi Healthcare; the Mayo Clinic, which is investigating virtual care models with the company; and Anthem, which has white labeled the K Health service and provides it to some of the insurer’s millions of members.
As the vaccination campaign to counter COVID-19 gets underway (albeit with a rocky start), a number of companies are attempting to support its rollout in a variety of ways. Healthvana, a health tech startup that began with a specific focus on providing patient information digitally for individuals living with HIV, is helping Los Angeles County roll-out mobile vaccination records for COVID-19 using Apple’s Wallet technology. A cursory appraisal of the implementation of this tech might lead one to believe it’s about providing individuals with easy proof of vaccination – but the tech, and Healthvana, are focused on informing individuals to ensure they participate in their own healthcare programs, not providing an immunity pass.
“I generally consider most of healthcare to look and feel like Windows 95,” Healthvana CEO and founder Ramin Bastani. “We look and feel like Instagram . Why is that important? Because patients can engage in things they understand, it’s easier for them to communicate in the way they’re used to communicating, and that ends up leading them better health outcomes.”
Bastani points out that they began the company by focusing this approach to patient education and communication on HIV, and demonstrated that using their software led to patients being 7.4 times more likely to show up for their next follow-up appointment vs. patients who received follow-up information and appointment notices via traditional methods. The company has built their tooling and their approach around not only producing better health for individuals, but also on reducing costs for healthcare providers by eliminating the need for a lot of the work that goes into clearing up misunderstandings, and essentially hounding patients to follow-up, which can significantly dig into clinician and care staff hours.
“We’re actually also reducing the cost to healthcare providers, because you don’t have 1,000 people calling you asking what are their results, and saying ‘I don’t understand, I can’t log in, I don’t know what it means to be SARS nonreactive,’ or all those things we address through simplicity,” Bastain said. “That’s made a huge difference. Overall, I think the key to all healthcare is going to be to be able to get patients to pay attention, and take action to things around their health.”
That’s the goal of Healthvana’s partnership with LA County on COVID-19 immunization records, too – taking vitally important action to ensure the successful rollout of its vaccination program. All approved COVID-19 vaccines to date require a two-course treatment, including one initial inoculation followed by a booster to be administered sometime later. Keeping LA county residents informed about their COVID-19 inoculation, and when they’re due for a second dose, is the primary purpose of the partnership, and benefits from Healthvana’s experience in improving patient follow-up activities. But the app is also providing users with information about COVID-19 care, and, most usefully, prevention and ways to slow the spread.
While Bastani stresses that Healthvana is, in the end, just “the last mile” for message delivery, and that there are many other layers involved in determining the right steps for proper care and prevention, the way in which they provide actionable info has already proven a big boon to one key measure: contact tracing. In select municipalities, Healthvana will also prompt users who’ve tested positive to anonymously notify close contacts directly from their device, which will provide those individuals with both free testing options and information resources.
“Just us doing this in the greater Los Angeles area for less than two months, 12,000+ people have been notified that they’ve been exposed,” Bastani said. “Each of them likely lives with other people and families – this is how you can help slow the spread.”
Contrast that with the relatively slow uptake of the exposure notification tools built into iOS and Android devices via recent software updates provided by Google and Apple working in a rare collaboration. While the technology that underlies it is sound, and focused on user privacy, its usage numbers thus far are far from earthshaking; only 388 people have sent alerts through Virginia’s app based on the exposure notification framework in three months since its launch, for instance.
Healthvana’s focus on timely and relevant delivery of information, offered to users in ways they’re mostly likely to understand and engage with, is already showing its ability to have an impact on COVID-19 and its community transmission. The startup is already in talks to launch similar programs elsewhere in the country, and that could help improve national vaccination outcomes, and how people handle COVID-19 once they have it, too.
Six years after launching its service linking employer-sponsored insurance plans with surgical centers of excellence, Carrum Health has raised $40 million in a new round of financing to capitalize on tailwinds propelling its business forward.
As the COVID-19 pandemic exposes cracks in the U.S. healthcare system, one of the ways that employers have tried to manage the significant costs of insuring employees is by taking on the management of care themselves.
As they shoulder more of the burden, companies like Carrum, which offer services that manage some of the necessary points of care for businesses, at lower costs, are becoming increasingly attractive targets for investors.
That’s why Carrum was able to attract investors led by Tiger Global Management, GreatPoint Ventures and Cross Creek, all firms that joined returning investors Wildcat Venture Partners and SpringRock Ventures in backing the company’s Series A round.
Carrum said the money will go toward sales and marketing to more customers, adding more services and improving its existing technology stack.
Carrum uses machine learning to collect and analyze data on surgical outcomes and care to identify what it considers to be surgical centers of excellence across the U.S.
The company offers self-insured employers the opportunity to buy services directly from surgical centers for a bundled price. That can mean savings of up to 50% on surgical expenses.
Using Carrum, there are no co-pays, deductibles or co-insurance. Instead, Carrum Health’s customers pay a fee and in return receive a 30-day warranty on procedures, meaning that the healthcare provider will cover any costs associated with care from botched operations or complications.
Employees have access to a mobile application that gives them access to virtual care before, during and after surgeries.
“For years, the industry has talked about redesigning healthcare to benefit patients, but the only way to really do that is to tackle the underlying economics of care, a truly difficult task,” said Sach Jain, CEO and founder of Carrum Health, in a statement. “Employers now have a modern, technology-driven solution to help patients get better care without financial headache and we’re not stopping at surgery. In 2021 we’ll be expanding our reach and impact with additional services. It’s such an honor to pave the way for a better healthcare future and we’re so excited for what’s to come.”
Carrum Health’s customers include Quest Diagnostics, US Foods, and other, undisclosed organizations in retail, manufacturing, communications and insurance, the company said.
Healthcare startup Color has raised a sizable $167 million in Series D funding round, at a valuation of $1.5 billion post-money, the company announced today. This brings the total raised by Color to $278 million, with its latest large round intended to help it build on a record year of growth in 2020 with even more expansion to help put in place key health infrastructure systems across the U.S. — including those related to the “last mile” delivery of COVID-19 vaccines.
This latest investment into Color was led by General Catalyst, and by funds invested by T. Rowe Price, along with participation from Viking Global investors as well as others. Alongside the funding, the company is also bringing on a number of key senior executives, including Claire Vo (formerly of Optimizely) as chief product officer, Emily Reuter (formerly of Uber, where she played a key role in its IPO process) as VP of Strategy and Operations, and Ashley Chandler (formerly of Stripe) as VP of Marketing.
“I think with the [COVID-19] crisis, it’s really shone the light on that lack of infrastructure. We saw it multiple times, with lab testing, with antigen testing and now with vaccines,” Color CEO and co-founder Othman Laraki told me in an interview. “The model that we’ve been developing, that’s been working really well and we feel like this is the opportunity to really scale it in a very major way. I think literally what’s happening is the building of the public health infrastructure for the country that’s starting off from a technology-first model, as opposed to, what ends up happening in a lot of industries, which is you start off taking your existing logistics and assets, and add technology to them.”
Color’s 2020 was a record year for the company, thanks in part to partnerships like the one it formed with San Francisco to establish testing for healthcare workers and residents. Laraki told me they did about five-fold their prior year’s business, and while the company is already set up to grow on its own sustainably based on the revenue it pulls in from customers, its ambitions and plans for 2021 and beyond made this the right time to help it accelerate further with the addition of more capital.
Laraki described Color’s approach as one that is both cost-efficient for the company, and also significant cost-saving for the healthcare providers it works with. He likens their approach to the shift that happened in retail with the move to online sales — and the contribution of one industry heavyweight in particular.
“At some point, you build Amazon — a technology-first stack that’s optimized around access and scale,” Laraki said. “I think that’s literally what we’re seeing now with healthcare. What’s kind of getting catalyzed right now is we’ve been realizing it applies to the COVID crisis, but also, we started actually working on that for prevention and I think actually it’s going to be applying to a huge surface area in healthcare; basically all the aspects of health that are not acute care where you don’t need to show up in hospital.”
Ultimately, Color’s approach is to rethink healthcare delivery in order to “make it accessible at the edge directly in people’s lives,” with “low transaction costs,” in a way that’s “scalable, [and] doesn’t use a lot of clinical resourcing,” Laraki says. He notes that this is actually very possible once you reasses the problem without relying on a lot of accepted knowledge about the way things are done today, which result in a “heavy stack” versus what you actually need to deliver the desired outcomes.
Laraki doesn’t think the problem is easy to solve — on the contrary, he acknowledges that 2021 is likely to be even more difficult and challenging than 2020 in many ways for the healthcare industry, and we’ve already begun to see evidence of that in the many challenges already faced by vaccine distribution and delivery in its initial rollout. But he’s optimistic about Color’s ability to help address those challenges, and to build out a “last mile” delivery system for crucial care that expands accessibility, while also making sure things are done right.
“When you take a step back, doing COVID testing or COVID vaccinations … those are not complex procedures at all — they’re extremely simple procedures,” he said. “What’s hard is doing them massive scale and with a very low transaction cost to the individual and to the system. And that’s a very different tooling.”
Dozens of medical imaging devices built by General Electric are secured with hardcoded default passwords that can’t be easily changed, but could be exploited to access sensitive patient scans, according to new findings by security firm CyberMDX.
The researchers said that an attacker would only need to be on the same network to exploit a vulnerable device, such as by tricking an employee into opening an email with malware. From there, the attacker could use those unchanged hardcoded passwords to obtain whatever patient data was left on the device or disrupt the device from operating properly.
CyberMDX said X-ray machines, CT and MRI scanners, and ultrasound and mammography devices are among the affected devices.
GE uses hardcoded passwords to remotely maintain the devices. But Elad Luz, head of research at CyberMDX, said some customers were not aware that their devices had vulnerable devices. Luz described the passwords as “hardcoded,” because although they can be changed, customers have to rely on a GE engineer to change the passwords on-site.
The vulnerability has also prompted an alert by Homeland Security’s cybersecurity advisory unit, CISA. Customers of affected devices should contact GE to change the passwords.
Hannah Huntly, a spokesperson for GE Healthcare, said in a statement: “We are not aware of any incident where this potential vulnerability has been exploited in a clinical situation. We have conducted a full risk assessment and concluded that there is no patient safety concern. Maintaining the safety, quality, and security of our devices is our highest priority.”
It’s the latest find by the New York-based healthcare cybersecurity startup. Last year the startup also reported vulnerabilities in other GE equipment, which the company later admitted could have led to patient injury after initially clearing the device for use.
CyberMDX, which works primarily to secure medical devices and improve hospital network security through its cyber intelligence platform while conducting security research on the side, raised $20 million earlier this year, just a month into the COVID-19 pandemic.
Sanguina, an Atlanta-based health technology developer, is launching its a mobile app in the Google Play Store that uses pictures of fingernails to determine whether or not someone is getting enough iron.
The app measures hemoglobin levels, which are a key indicator of anemia, by analyzing the color of a person’s fingernail beds in a picture.
These fingernail selfies could be used to determine anemia for the more than 2 billion people who are affected by the condition — including women, children, athletes and the elderly.
Iron deficiencies can cause fatigue, pregnancy complications, and in severe cases, even cardiac arrest, the company said. AnemoCheck is the first smartphone application to measure hemoglobin levels, the company said — and through its app people can not only determine whether or not they’re anemic but also use the app’s information to address the condition, the company said.
Sanguina’s technology uses an algorithm to determine the amount of hemoglobin in the blood based on an examination and analysis of the coloration of the nail bed.
Created by Dr. Wilbur Lam, Erika Tyburski, and Rob Mannino, the company was born out of research conducted at the Georgia Institute of Technology and Emory University.
“This non-invasive anemia detection tool is the only type of app-based system that has the potential to replace a common blood test,” said Dr. Lam, a clinical hematologist-bioengineer at the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta, associate professor of pediatrics at Emory University School of Medicine, and a faculty member in the Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Tech.
So far, Sanguina has raised over $4.2 million in funding from The Seed Lab, XRC Labs, as well as grants from The National Science Foundation and The National Institutes of Health, according to a statement.
Like Amazon, China’s e-commerce firms Alibaba and JD.com have been working to conquer the massive healthcare industry. The offerings are wide-ranging, reaching everything from around-the-clock delivery of medicines, sale of consumer health services like plastic surgery, online diagnosis for patients, to digital solutions for hospitals (like appointment-booking) and advertising services for drugmakers.
Alibaba Health began as an investment portfolio of the e-commerce firm and grew into a subsidiary through episodes of consolidations over the years. JD Health, on the other hand, was spun out from JD.com in 2019 and quickly began to attract flows of large investments.
The move into healthcare is part of the behemoths’ goal to be a one-stop-shop for everything. Here are some numbers for gauging how the digital health giants compare with each other:
In terms of revenue sources, both companies rely mostly on the sales of medicines (both over-the-counter and prescription) and other healthcare products like vitamin supplements. Both have a direct-to-consumer drug business, whereby they are more involved in the supply chains, but they also serve as a marketplace for third-party suppliers, in which case they monetize by charging commission fees. They each have a smaller but growing services segment targeting consumers, hospitals and pharmaceutical companies.
Alibaba Health – 7 billion yuan or $1.07 billion (six months ended September)
JD Health – 8.8 billion yuan or $1.35 billion (six months ended June)
Alibaba Health posted its first profitable earnings this year, pocketing 278.6 million yuan in the six months ended September, up from a loss of 7.6 million yuan from the same period last year.
In the six months ended June, JD Health incurred a loss of 5.4 billion yuan, compared to a profit of 236.3 million yuan in the same period of 2019. The loss was mainly due to fair value changes after issuing additional convertible preferred shares.
Though Alibaba Health generated less revenue, the platform enjoys a larger user base, thanks to Alibaba’s sprawling ecosystem. In the year ended June, a total of 250 million users made purchases through the online pharmacy of Tmall, Alibaba’s business-to-consumer marketplace. Meanwhile, Alibaba Health’s direct-to-consumer drugstore saw 65 million annual active users.
In comparison, 72.5 million people had at least made one purchase through JD Health’s platform in the past year.
Both companies provide online health consultation services, which saw a surge in demand during the COVID-19 outbreak. Alibaba Health had a network of over 39,000 doctors by September, compared to JD Health’s pool of over 65,000 doctors, both in-house and third-party.
Drugmaker Moderna has completed its initial efficacy analysis of its COVID-19 vaccine from the drug’s Phase 3 clinical study, and determined that it was 94.1% effective in preventing people from contracting COVID-19 across 196 confirmed cases from among 30,000 participants in the study. Moderna also found that it was 100% effective in preventing severe cases (such as those that would require hospitalization) and says it hasn’t found any significant safety concerns during the trial. On the basis of these results, the company will file an application for emergency use authorization (EUA) with the U.S. Food and Drug Administration (FDA) on Monday.
Seeking an EUA is the next step towards actually beginning to distribute and administer Moderna’s COVID-19 vaccine, and if granted the authorization, it will be able to provide it to high-risk individuals in settings where it could help prevent more deaths, such as with front-line healthcare workers, ahead of receiving a full and final regulatory approval from the U.S. healthcare monitoring agency. Moderna will also seek conditional approval from the European Medicines Agency, which will enable similar use ing the EU.
Moderna’s vaccine is an mRNA vaccine, which provides genetic instructions to a person’s body that prompts them to create their own powerful antibodies to block the receptor sites that allows COVID-19 to infect a patient. It’s a relatively new therapeutic approach for human use, but has the potential to provide potentially even more resistance to COVID-19 than do natural antibodies, and without the risk associated with introducing any actual virus, active or otherwise, to an inoculated individual in order to prompt their immune response.
In mid-November, Moderna announced that its COVID-19 vaccine showed 94.5% efficacy in its preliminary results. This final analysis of that same data hews very close to the original, which is promising news for anyone hoping for an effective solution to be available soon. This data has yet to be peer reviewed, though Moderna says that it will now be submitting data from the Phase 3 study to a scientific publication specifically for that purpose.
Moderna’s vaccine candidate is part of the U.S’s Operation Warp Speed program to expedite the development, production and distribution of a COVID-19 vaccine, initiated earlier this year as a response to the unprecedented global pandemic. Other vaccines, including one created by Pfizer working with partner BioNTech, as well as an Oxford University/AstraZeneca-developed candidate, are also far along in their Phase 3 testing and readying for emergency approval and use. Pfizer has already applied with the FDA for its own EUA, while the Oxford vaccine likely won’t be taking that step in the U.S. until it completes another round of final testing after discovering an error in the dosage of its first trial – which led to surprising efficacy results.
Resilience, a new biopharmaceutical company backed by $800 million in financing from investors including ARCH Venture Partners and 8VC, has emerged from stealth to transform the way that drugs and therapies are manufactured in the U.S.
Founded by ARCH Venture Partners investor Robert Nelsen, National Resilience Inc., which does business as Resilience was born out of Nelsen’s frustrations with the inept American response to the COVID-19 pandemic.
According to a statement the company will invest heavily in developing new manufacturing technologies across cell and gene therapies, viral vectors, vaccines and proteins.
Resilience’s founders identified problems in the therapeutic manufacturing process as one of the key problems that the industry faces in bringing new treatments to market — and that hurdle is exactly what the company was founded to overcome.
“COVID-19 has exposed critical vulnerabilities in medical supply chains, and today’s manufacturing can’t keep up with scientific innovation, medical discovery, and the need to rapidly produce and distribute critically important drugs at scale. We are committed to tackling these huge problems with a whole new business model,” said Nelsen in a statement.
The company brings together some of the leading investment firms in healthcare and biosciences including operating partners from Flagship Pioneering like Rahul Singhvi, who will serve as the company’s chief executive’ former Food and Drug Administration commissioner Scott Gottlieb, a partner at New Enterprise Associates and director on the Resilience board; and Patrick Yang, the former executive vice president and global head of technical operations at Roche/Genentech .
“It is critical that we adopt solutions that will protect the manufacturing supply chain, and provide more certainty around drug development and the ability to scale up the manufacturing of safe, effective but also more complex products that science is making possible,” said Dr. Gottlieb, in a statement. “RESILIENCE will enable these solutions by combining cutting edge technology, an unrivaled pool of talent, and the industry’s first shared service business model. Similar to Amazon Web Services, RESILIENCE will empower drug developers with the tools to more fully align discovery, development, and manufacturing; while offering new opportunities to invest in downstream innovations in formulation and manufacturing earlier, while products are still being conceived and developed.”
Other heavy hitters in the world of medicine and biotechnology who are working with the company include Frances Arnold, the Nobel Prize-winning professor from the California Institute of Technology; George Barrett, the former chief executive of Cardinal Health; Susan Desmond-Hellmann, the former president of product development at Genentech; Kaye Foster, the former vice president of human resources at Johnson and Johnson; and Denice Torres, the former President of Johnson & Johnson Pharmaceutical and Consumer Companies.
Arturo Sanchez and his co-founders have spent the past two years developing the telemedicine and insurance platform, Sofia, as a way to give customers across Mexico better access to quality healthcare through their insurance plan.
Along with his co-founders, Sebastian Jimenez, a former Google employee who serves as the company’s chief product officer, and Manuel Andere an ex-Patreon employee who’s now Sofia’s chief technology officer, Sanchez (a former Index Ventures employee) is on a path to provide low-cost insurance for middle class consumers across Latin America, starting in Mexico City.
Backing that vision are a clutch of regional and international investors including Kaszek Ventures, Ribbit Capital, and Index Ventures. When Index Ventures came in to lead the company’s $19 million round earlier this year, it was the first commitment that the venture firm had made in Latin America, but given the strength of the market, it likely won’t be their last.
In Sofia, Index has found a good foothold from which to expand its activity. The company which initially started as a telemedicine platform recently received approvals to operate as an insurer as well — part of a long-term vision for growth where it provides a full service health platform for customers.
Founded by three college friends who graduated from the Instituto Tecnológico Autónomo de México (Mexico’s version of MIT), the company initially launched with COVID-19 related telemedicine service as the pandemic took hold in Mexico.
That service was a placeholder for what Sanchez said was the broader company vision. And while that product alone had 10,000 users signed up for it, the new vision is broader.
“We registered as an insurance company because we want to go deeper into people’s health. We have built a telemedicine solution, which is a core component of the product. The goal is to be an integrated provider that provide primary care and handles more significant types of illnesses,” said Sanchez.
The company already has a core group of 100 physicians in Mexico City and initially will be serving the city with 70 different specialist areas.
All the virtual consultations are covered without an additional payment and in-person or specialty consultations come at a 30% reduced rate to an out-of-pocket payment, according to Sanchez.
Fees depend on age and gender, but Sanchez said a customer would typically pay around $500 per-year or roughly between $40 and $50 per-month.
The company covers 70% of the cost of most treatments that’s capped at $2,000 per-year and coverage maxes out at $75,000. “In Mexico that covers north of 98% of all illnesses or treatment episodes,” said Sanchez.
In Mexico, insurance is even less common than in the US.
“90% of private health spend happens out of pocket. The problem that we’re trying to solve is for these people that are already spending money on healthcare but doing it in an unpredictable and risky way,” said Sanchez. “They buy [our service] and they have access to great quality healthcare that they buy it and it’s a significant step up from what they’ve been living with.”
The software provides real-time feedback on documentation and coding.
Coding problems can be the difference between success and failure for hospitals, according to Diagnoss. Healthcare providers were decimated by the COVID-19 outbreak, with hospitals operating below 60% capacity and one-fourth of them facing the potential for closing in a year if the pandemic continues to disrupt care.
The cost pressures mean that any coding error can be the financial push that forces a healthcare provider over the edge.
“For every patient encounter, a physician spends an average of 16 minutes on administration, which adds up to several hours every single day. In addition, codes entered are often wrong – up to a 30% error rate – resulting in missed or delayed reimbursements. We believe that, with the great progress we’ve seen with artificial intelligence and machine learning, we can finally address some of these inefficiencies that are leading to physician burnout and financial strain,” said Abboud Chaballout, founder and chief executive of Diagnoss, in a statement.
Diagnoss acts like a grammar checking tool, but its natural language processing software is focused on reading doctor’s notes. The company’s tools can provide evaluation and management code for patient encounters; point out missing information in doctors’ notes; and provide predictions about the diagnosis and procedure codes that could apply after reviewing a doctor’s notes.
In a study of 39,000 de-identified EHR charts, the company found that its machine coding service was about 50% more accurate than human coders, according to a Diagnoss review.
Physician practices are already using Diagnoss’ service through a previously announced partnership with the mobile EHR vendor, DrChrono .
SoftBank’s Opportunity Growth Fund has made the health insurance startup Vitable Health the first commitment from its $100 million fund dedicated to investing in startups founded by entrepreneurs of color.
The Philadelphia-based company, which recently launched from Y Combinator, is focused on bringing basic health insurance to underserved and low-income communities.
Founded by Joseph Kitonga, a 23 year-old entrepreneur whose parents immigrated to the U.S. a decade ago, Vitable provides affordable acute healthcare coverage to underinsured or un-insured populations and was born out of Kitonga’s experience watching employees of his parents’ home healthcare agency struggle to receive basic coverage.
The $1.5 million commitment was led by the SoftBank Group Corp Opportunity Fund, and included Y Combinator, DNA Capital, Commerce Ventures, MSA Capital, Coughdrop Capital, and angels like Immad Akhund, the chief executive of Mercury Bank; and Allison Pickens, the former chief operating officer of Gainsight, the company said in a blog post.
“Good healthcare is a basic right that every American deserves, whoever they are,” said Paul Judge, the Atlanta-based Early Stage Investing Lead for the fund and the founder of Atlanta’s TechSquare Labs investment fund. “We’ve been inspired by Joseph and his approach to addressing this challenge. Vitable Health is bridging critical gaps in patient care and has emerged as a necessary, essential service for all whether they’re uninsured, underinsured, or simply need a better plan for their lifestyle.”
SoftBank created the opportunity fund while cities around the U.S. were witnessing a wave of public protests against systemic racism and police brutality stemming from the murder of the Black Minneapolis citizen George Floyd at the hands of white police officers. Floyd’s murder reignited simmering tensions between citizens and police in cities around the country over issues including police brutality, the militarization of civil authorities, and racial profiling.
SoftBank has had its own problems with racism in its portfolio this year. A few months before the firm launched its fund, the CEO and founder of one of its portfolio companies, Banjo, resigned after it was revealed that he once had ties to the KKK.
With the Opportunity Fund, SoftBank is trying to address some of its issues, and notably, will not take a traditional management fee for transactions out of the fund “but instead will seek to put as much capital as possible into the hands of founders and entrepreneurs of color.”
The Opportunity Fund is the third investment vehicle announced by SoftBank in the last several years. The biggest of them all is the $100 billion Vision Fund; then last year it announced the $2 billion Innovation Fund focused on Latin America.